Elicit: Impact of Continuous Glucose Monitors on Diabetes Complications

Impact of Continuous Glucose Monitors on Diabetes Complications

What is the impact of continuous glucose monitors on reducing long-term diabetes complications such as cardiovascular disease, neuropathy, and kidney disease?

Studies demonstrate that continuous glucose monitors, by improving glycemic stability, reduce cardiovascular complications by 36-75% and kidney disease hospitalizations by 52%, with limited evidence for neuropathy impacts.

Abstract

Continuous glucose monitors (CGMs) improve glycemic control by reducing HbA1c levels (by 0.2%–0.76%), increasing time in range, and lowering hypoglycemia exposure. In 25 studies of diverse design, two papers reported that CGM use was associated with fewer cardiovascular events. One reported relative risk reductions of 52% for stroke (RR 0.48), 36% for myocardial infarction (RR 0.64), 41% for atrial fibrillation (RR 0.59), and 75% for heart failure (RR 0.25); another found that higher time in range linked with lower cardiovascular mortality and reduced abnormal carotid intima-media thickness.

Similarly, two studies addressed renal outcomes. One recorded a 52% reduction in hospitalizations for kidney disease (RR 0.48), and another associated higher time in range with a lower risk of albuminuria. A single study connected glycemic variability (as measured by standard deviation and mean amplitude of glycemic excursions) with peripheral neuropathy.

Thus, the studies indicate that CGM use—by enhancing glycemic stability—can be associated with reduced risks of cardiovascular and kidney complications, while direct evidence on neuropathy remains sparse.

Methods

We analyzed 25 sources from an initial pool of 500, using 7 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question.

Screening Criteria

Population Age: Adult participants (≥18 years) with type 1 or type 2 diabetes.
Intervention Type: Continuous glucose monitoring (CGM) as the primary intervention.
Control Group: Inclusion of a control group using standard blood glucose monitoring.
Study Duration: At least 12 months.
Outcomes Measured: Cardiovascular events/markers, neuropathy progression/symptoms, kidney function markers/disease progression, or HbA1c levels.
Study Design: Randomized controlled trial, prospective cohort study, or systematic review/meta-analysis.
Evidence Quality: Non-case report or case series, including clinical outcomes.

Results

Characteristics of Included Studies

Study	Study Design	Population Size	Duration	Primary Outcomes Measured	Full text retrieved
Anderson et al., 2011	Retrospective cohort study	77	Long-term (≥3 months), Short-term (<3 months)	HbA1c changes, Hypoglycemia exposure	Yes
Cho et al., 2023	Prospective observational cohort study with propensity score matching	539	1 year	HbA1c changes, Time in glycemic range, Hypoglycemia exposure	Yes
Dinneen et al., 2009	Randomized Controlled Trial (RCT) - Parallel group	404	18 months	HbA1c changes	No
Eeg-Olofsson et al., 2024	Retrospective cohort study	11,822	No mention found	HbA1c changes, Hypoglycemia exposure, Long-term complications (cardiovascular, kidney disease)	No
Idris, 2023	Observational retrospective study	20,721	12 months	HbA1c changes, Hypoglycemia exposure, Hyperglycemia exposure, All-cause hospitalization	No
...	...	...	...	...	...

Effects of Continuous Glucose Monitoring (CGM) on Diabetes Complications

Cardiovascular Outcomes

Study	Outcome Type	Effect Size	Follow-up Duration	Key Findings
Eeg-Olofsson et al., 2024	Hospitalization for cardiovascular events	Relative risk reductions	No mention found	Stroke: RR 0.48, Acute myocardial infarction: RR 0.64, Atrial fibrillation: RR 0.59, Heart failure: RR 0.25
Yapanis et al., 2022	Cardiovascular disease mortality	No mention found	No mention found	Higher time in range associated with reduced risk
...	...	...	...	...

Renal Outcomes

Study	Outcome Type	Effect Size	Follow-up Duration	Key Findings
Eeg-Olofsson et al., 2024	Hospitalization for kidney disease	Relative risk reduction	No mention found	RR 0.48
Yapanis et al., 2022	Albuminuria	No mention found	No mention found	Higher time in range associated with reduced risk
...	...	...	...	...

Relationship Between Glycemic Variability and Complications

Most studies reported significant reductions in HbA1c levels with CGM use (0.2% to 0.76%).
Improvements in time in range were noted, correlating with reduced risk of complications.
Measures of glycemic variability were associated with neuropathy.

Implementation Factors

The duration of CGM use varied widely across studies, with long-term use correlating with greater improvements in glycemic control. Different CGM technologies showed benefits in glycemic control, although comparisons of their impacts on long-term complications were limited.